Effect of CYP2C9 and VKORC1 genotype on inter-individual warfarin dose - A prospective study in Chinese population

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54178709

Enrollment

400

Registered

2007-07-26

Start date

2006-06-01

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not applicable Not Applicable Not applicable

Interventions

1. Retrospective study We enrolled 200 patients undergoing stable warfarin anticoagulation therapy. An algorithm has been established based on patients? personal data including gender,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who will initiate warfarin administration 2. Aged 18 years or more 3. Written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Patients with previous and current liver disease 2. Renal failure (creatinine greater than 106 µmo/L) 3. Base coagulant response time (INR) is 1.4 or more 4. Patients using any other known drugs that related to CYP2C9 5. Use of warfarin in the past three months

Design outcomes

Primary

Measure	Time frame
1. Difference in stable warfarin doses among patients with genotypes CYP2C9 and VKORC1 2. An algorithm of stable warfarin dose established using multiple linear-regression equation 3. To assess the feasibility of the algorithm for treatment group compared to control group on: 3.1. Days until a stable therapeutic INR (2.0-3.0) 3.2. Days until an adverse outcome	—

Secondary

Measure	Time frame
1. INR, measured every day during hospitalization and twice a week after discharge 2. Warfarin dose, recorded every day 3. Adverse outcome, recorded every day	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026